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Ouraimistodetermine—in30healthyfull-terminfantsandtheirmothers—circulatinglevelsofneurotrophin-3(NT-3)(important
for antenatal and postnatal brain development and implicated in the immune response) and FLT3 tyrosine kinase receptor (FLT3)
(controlling hematopoiesis and found in the nervous tissue), in the fetal and neonatal life. NT-3 levels, in contrast to FLT3 ones,
increasedsigniﬁcantlyonthefourthpostnataldayinrelationtothelowlevelsfoundinthemother,fetus,andday1neonate(P = .03,
respectively).MaternalandumbilicalNT3levelspositivelycorrelatedwithrespectiveFLT3levels(P = .003andP = .03).Circulating
NT-3 levels increased in early neonatal life, possibly due to exposure to various stimuli soon after birth. FLT3 levels do not seem to
behave accordingly, although these two substances probably synergize.
INTRODUCTION
Neurotrophin-3 (NT-3) belongs to the neurotrophin
family, which includes, among others, the nerve growth
factor and the brain-derived neurotrophic factor (BDNF)
[1]. Neurotrophins exert antiapoptotic activities in neu-
rons [2] and are implicated in higher neuronal functions
[3] and neurotransmitter expression [4]. Therefore, neu-
rotrophins may play important roles in antenatal and
postnatal brain development. In addition, neurotrophins
are involved in the immune response [5, 6, 7, 8]. More-
over, nerve growth factor, BDNF, and NT-3 act on tyro-
sine kinase A, B, and C receptors, respectively. It has re-
cently been reported that in neonatal age circulating neu-
rotrophin levels could reﬂect the degree of neuronal ma-
turity [1], since, at this age, due to the immature blood-
brain barrier, neurotrophin blood levels may also repre-
sent concentrations in the CNS [9].
The FLT3 receptor (FLT3) is a member of the class III
receptor tyrosine kinases [10]. Related members of this
family of receptors together with their respective ligands
have been shown to control numerous distinct stages of
hematopoiesis[11,12].Recently,regionsofthebrainhave
been shown to harbor neural stem/progenitor cells that
retain the capacity to proliferate and to give rise to new
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cells throughout the lifetime of an animal [10, 13]. Thus,
they generate neurons, oligodendrocytes, astrocytes, but
also retain the ability to repopulate hematopoietic sys-
tems of irradiated animals [14] and to give rise to multi-
ple tissue types when grown in the presence of embryonic
stem cells [15]. On the other hand, hematopoietic stem
cells have been shown to give rise to neurons, when trans-
planted into mice [16, 17, 18, 19]. In this respect, many
studies have conﬁrmed the presence of FLT3 mRNA in
nervous tissue [20, 21].
This study was based on the hypothesis that a possible
interaction between hematopoietic and neuronal activity
in the central nervous system, possibly also representing
the state of maturity, might be reﬂected in the periphery.
Thus, we aimed to determine circulating levels of NT-3
and FLT3 in full-term neonates and correlate these levels
with gestational age, gender, and mode of delivery.
MATERIALS AND METHODS
The study was approved by the Ethics Committee
of our teaching hospital and informed consent was ob-
tained from participating mothers. The study included
30 healthy, infection-free, nonsmoking parturients (mean
age: 25.6 ± 3.4, range: 20–40 years) and their healthy
neonates appropriate for gestational age and born af-
ter single uncomplicated pregnancy and delivery. Apgar
scores were ≥ 8 in the ﬁrst and ﬁfth minutes. Placen-
tas were in all cases normal in appearance and weight.
CompletebloodcountandC-reactiveproteinwerewithin
normal ranges in all newborns. All infants received breast54 Ariadne Malamitsi-Puchner et al 2005:1 (2005)
Table 1. Demographic data of participating full-term (n = 30)
neonates.
Gestational
age (weeks)
Mean ±SD 39.2 ±1.4
Range 37–41
Gender
(male/female) 17/13
Mode of
delivery
Vaginal 20
Elective cesarean section 10
milk. Developed jaundice required phototherapy treat-
ment in 5 infants. Demographic data of participating
neonates are shown in Table 1.
The study assessed circulating levels of NT-3 and
FLT3. Thus, blood was taken from (a) the mothers (MS)
before delivery (at the ﬁrst stage of labor, or before re-
ceiving anesthesia in cases of elective cesarean section),
(b) the doubly clamped umbilical cord (UC) at deliv-
ery (UC representing fetal state), and the neonates (c)
on the ﬁrst (N1) and (d) fourth days (N4). The blood
was collected in pyrogen-free tubes; following centrifuga-
tion the supernatant serum and EDTA plasma were kept
frozen at −80◦C until assay. NT-3 and FLT3 were deter-
mined in serum and EDTA-plasma, respectively, by en-
zyme immunoassays (R&D Systems Minneapolis, Minn
55413, catalogue numbers DY 267 and DFK 00, respec-
tively). The minimum detectable concentration, intraas-
say and interassay coeﬃcients of variations were for NT-3
1pg/mL,8.7%and14.9%,andforFLT3lessthan7pg/mL,
2.7% and 11.1%, respectively.
STATISTICAL ANALYSIS
Variableswerecheckedfornormalityoftheirdistribu-
tion by Kolmogorov-Smirnov one-sample test. Data not
normallydistributedwerelog10transformed(NT-3MS).
Unpaired and paired t test was used in the analysis. Fur-
thermore, Pearson correlation coeﬃcient was calculated.
RESULTS
The circulating NT-3 and FLT3 levels in MS, UC, N1,
a n dN 4a r ep r e s e n t e di nTable 2. Statistically signiﬁcant
diﬀerences were found in NT-3 levels between MS and
N4 (P = .03), UC and N4 (P = .03), and N1 and N4
(P = .03).Ontheotherhand,FLT3circulatingconcentra-
tions did not present any diﬀerence between the various
samples. In addition, MS NT-3, as well as UC NT-3 levels,
positivelycorrelatedwithrespectiveFLT3levels(P = .003,
and P = .03). No correlation with gender, gestational age,
o rm o d eo fd e l i v e r yw a sf o u n df o re i t h e rN T - 3o rF L T 3 .
DISCUSSION
The results of this study indicate that NT-3 serum
concentrations rise signiﬁcantly on the forth day of life,
from the low levels encountered in the umbilical cord and
ontheﬁrstpostnatalday.Nevertheless,suchrisecouldnot
be found concerning FLT3.
The signiﬁcant increase of NT-3 on the fourth post-
natal day may indicate its secretion from the nervous and
immune systems of the neonate, as a result of exposure
to various stimuli soon after birth. Respectively, in a re-
cent study we demonstrated that the BDNF circulating
levels increased signiﬁcantly in the postnatal period, as
compared to the fetal levels [22]. It has been stated that
neurotrophins are important for the physiological func-
tion of the peripheral as well as the central nervous sys-
tem, contributing to developmental maturity of the cor-
tex and plasticity of the synapses, leading to the reﬁne-
ment of connections [23]. In addition, previous studies
reported that neurotrophins are produced, stored, and re-
leased by various immune cells [24], and elevated plasma
levels are found in inﬂammatory, autoimmune, and aller-
gic diseases [8]. Transition of the infant to extrauterine
life, where he or she is exposed to a variety of antigenic
stimuli [25], including feeding [26], might be responsi-
ble for the postnatal signiﬁcant increase of NT-3. Fur-
thermore, it has been reported that the elevation of neu-
rotrophins might also be a consequence of proinﬂamma-
tory cytokines [27], the production of which then again is
inﬂuencedbytheformer[28].Accordingly,wehaveprevi-
ously demonstrated [29] a signiﬁcant increase in circulat-
ing levels of the proinﬂammatory cytokines interleukin-
1β, interleukin-6, and tumor necrosis factor-α in healthy
neonates soon after birth.
Lastly, one should consider a third parameter possi-
bly implicated in the increased postnatal circulating NT-3
levels: its secretion by vascular endothelial cells [30]. The
lattermultiplyandmigrate,contributingtotheformation
of new blood vessels from preexisting ones (angiogenesis)
[31], when rapid growth and development is taking place
[32], particularly in the third trimester of pregnancy [33],
and to a lesser extent in neonatal life.
It has been previously described that many cytokines
are shared by the haematopoietic and nervous systems
and they exert diﬀerent functions in diﬀerent contexts
[10]. Nerve growth factor can act as a colony-stimulating
factor, as it stimulates immature erythroleukemic cell
lines and bone-marrow-derived precursor cells to prolif-
erate [34]. FLT3 is most robustly expressed on diﬀeren-
tiated postmitotic neurons, whereas in the hematopoietic
system, immature cells preferentially express FLT3 [10].
The lack of increased FLT3 levels in fetal and neonatal
samples, according to this study, could possibly be at-
tributed to the fact that examined peripheral blood did
not contain immature hematopoietic cells, as neonates
were full term and infection free. On the other hand, it
has been shown that FLT3 does not play a role as a trophic
factor during the early stages of development within the
central nervous system [35].
Our ﬁnding that MS and UC NT-3 levels, positively
correlated with MS and UC FLT3 levels, respectively,
could be explained in parallel with the ability of FLT32005:1 (2005) NT-3 and FLT3 in Perinatal Life 55
Table 2. Circulating neurotrophin-3 (NT-3) and FLT3 tyrosine kinase receptor (FLT3) (mean±SD) levels (pg/mL) in mothers (MS),
umbilical cords (UC) and neonates on the ﬁrst (N1) and fourth (N4) days of full-term neonates (n = 30).
Blood sample NT-3 FLT3
MS 23.6 ±6.86 7 .9 ±5.9
UC 27.7 ±6.25 5 .5 ±3.5
Neonates (ﬁrst day) 23.6 ±3.26 0 .9 ±3.4
Neonates (fourth day) 43.6 ±12.75 9 .1 ±3.4
to synergize with NGF, thus to enhance the competence
of neurons to respond to neurotrophins [10]. However,
a further explanation could take into account the inter-
actions of the nervous and immune systems, particularly
understresssituations,asithappensinlaboranddelivery.
In conclusion, circulating NT-3 levels increase during
theearlyneonatallife.However,circulatingFLT3levelsdo
not seem to behave accordingly, although these two sub-
stances probably synergize.
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